BIOMAT Database Logo BIOMAT Database Logo

[Double-blind evaluation of mepartricin 150.000 U (40 mg) compared with placebo in benign prostatic hypertrophy]. 1996

D Prezioso, and V Mirone, and F Fabrizio, and T Lotti
Cattedra di Urologia, II Facoltà di Medicina, Università degli Studi, Napoli.

The therapeutic efficacy and tolerance of a new 150,000 U (40 mg) formulation of mepartricin (to be administered once-a-day in the evening) were evaluated during a double-blind study against placebo in 2 groups of uncomplicated BPH patients treated for 60 days. The data obtained disclosed a positive pharmaco-therapeutic effect of this new formulation coupled with excellent local and systemic tolerance. At the end of trial the various objective and subjective parameters considered showed marked improvement in the group treated with mepartricin, with statistically significant differences from the placebo-treated group. The treatment efficacy was judged positive in 74-78% of cases by patients and physicians in the mepartricin group and in 36.4% of cases in the placebo group.

UI MeSH Term Description Entries
D008297 Male Males
D008613 Mepartricin Polyene macrolide antibiotic with unknown composition. It is obtained from Streptomyces aureofaciens. It is used as an antifungal agent, an antiprotozoal agent, and in the treatment of BENIGN PROSTATIC HYPERTROPHY. Methylpartricin,Mepartricin A,Mepartricin B,Methyl Partricin,SPA-S 160,Tricandil,SPA S 160,SPAS 160
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

D Prezioso, and V Mirone, and F Fabrizio, and T Lotti
[Multicenter clinical study of the effects of once daily administration of mepartricin 150.000 U. in benign prostatic hypertrophy].
September 1995, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica,
D Prezioso, and V Mirone, and F Fabrizio, and T Lotti
[Randomized double-blind study using mepartricin and a placebo in the therapy of benign prostatic hypertrophy].
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
D Prezioso, and V Mirone, and F Fabrizio, and T Lotti
[Clinical evaluation of mepartricin in benign prostatic hypertrophy].
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
D Prezioso, and V Mirone, and F Fabrizio, and T Lotti
[Evaluation of the objective efficacy of mepartricin in benign prostatic hypertrophy].
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
D Prezioso, and V Mirone, and F Fabrizio, and T Lotti
Placebo-controlled double-blind study in human benign obstructive prostatic hypertrophy with flutamide.
January 1976, European urology,
D Prezioso, and V Mirone, and F Fabrizio, and T Lotti
[Clinical and echographic evaluation of a group of 40 patients suffering from benign prostatic hypertrophy treated with mepartricin].
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
D Prezioso, and V Mirone, and F Fabrizio, and T Lotti
[Clinical evaluation of the use of mepartricin in the therapy of prostatic hypertrophy. Double-blind study].
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
D Prezioso, and V Mirone, and F Fabrizio, and T Lotti
[Mepartricin as medical treatment of benign prostatic hypertrophy].
January 1993, Journal d'urologie,
D Prezioso, and V Mirone, and F Fabrizio, and T Lotti
[Mepartricin versus placebo in the therapy of prostatic hypertrophy].
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
D Prezioso, and V Mirone, and F Fabrizio, and T Lotti
[The effects of mepartricin on the symptomatology of prostatic hypertrophy--double-blind controlled trial].
January 1991, Acta urologica Belgica,
Copied contents to your clipboard!